


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of the claims in the application:

**Listing of Claims:**

1. (Original) A compound according to the general formula



or a pharmaceutically acceptable salt thereof, wherein:

R<sub>1</sub> is independently selected from: carboxylic acid (-CO<sub>2</sub>H); phosphonic acid (-PO(OH)<sub>2</sub>); phosphamic acid (-PO(OH)NH<sub>2</sub>); sulphonic acid (-SO<sub>2</sub>OH); hydroxamic acid (-CONHOH); oxamic acid (-NHCOCO<sub>2</sub>H); and malonamic acid (-NHCOCH<sub>2</sub>CO<sub>2</sub>H), or any other possible bioisosteric equivalent of the groups above;

R<sub>2</sub> and R<sub>3</sub> are the same or different and independently selected from: chlorine; bromine; iodide; C<sub>1-4</sub> alkyl, said alkyl, or a bioisosteric equivalent optionally substituted with 0, 1, 2 or 3 groups of R<sup>a</sup> which groups may be the same or different;

R<sub>4</sub> and R<sub>6</sub> are the same or different and independently selected from: hydrogen; halogen; C<sub>1-4</sub> alkyl; or a bioisosteric

equivalent optionally substituted with 0, 1, 2 or 3 groups of R<sup>a</sup> which groups may be the same or different;

R<sub>5</sub> is selected from: C<sub>6-10</sub> aryl; C<sub>1-9</sub> heteroaryl, said aryl; and heteroaryl optionally substituted with 0, 1, 2 or 3 groups of R<sup>b</sup> which groups may be the same or different;

R<sup>a</sup> represents fluorine or chlorine;

R<sup>b</sup> represents a member selected from the group of: halogen; -CN; -CO<sub>2</sub>H; -CHO; -NH<sub>2</sub>; C<sub>1-4</sub> alkyl; C<sub>2-4</sub> alkenyl; C<sub>2-4</sub> alkynyl; C<sub>1-4</sub> alkoxy; C<sub>2-4</sub> alkenoxy; C<sub>2-4</sub> alkynoxy; C<sub>1-4</sub> alkylthio; C<sub>2-4</sub> alkenylthio; C<sub>2-4</sub> alkynylthio; C<sub>6</sub> aryl; C<sub>1-5</sub> heteroaryl; C<sub>3-6</sub> cycloalkyl; -NH(C<sub>1-4</sub>); -N(C<sub>1-4</sub>)<sub>2</sub>; -NH(C<sub>6</sub>aryl); -N(C<sub>6</sub>aryl)<sub>2</sub>; -NH(C<sub>1-5</sub> heteroaryl); and -N(C<sub>1-5</sub> heteroaryl)<sub>2</sub> or a bioisosteric equivalent;

n is an integer of 1, 2 or 3;

included for the variables above are all the possible stereoisomers thereof; prodrug ester forms thereof; and radioactive forms thereof.

2. (Original) A compound according to claim 1 wherein R<sub>1</sub> is carboxylic acid (-CO<sub>2</sub>H).

3. (Currently Amended) A compound according to claim 1 ~~or 2~~ wherein R<sub>2</sub> and R<sub>3</sub> is bromine or chlorine.

4. (Currently Amended) A compound according to ~~any one of claims 1 to 3~~ claim 1, wherein R<sub>4</sub> is isopropyl and R<sub>6</sub> is hydrogen.

5. (Currently Amended) A compound according to ~~any one of claims 1, 2 or 4~~ claim 1, wherein R<sub>2</sub> and R<sub>3</sub> is bromine.

6. (Currently Amended) A compound according to ~~any one of claims 1 to 5~~ claim 1, which is:

{4,6-Dibromo-5-[3-isopropyl-4-(naphthalen-2-yl-methoxy)phenoxy]indan-1-yl}-acetic acid;

{4,6-Dibromo-5-[4-(4-fluorobenzyloxy)-3-isopropylphenoxy]indan-1-yl}acetic acid;

{4,6-Dibromo-5-[3-isopropyl-4-(5-methylisoxazol-3-ylmethoxy)phenoxy]indan-1-yl}acetic acid;

{4,6-Dibromo-5-[3-isopropyl-4-(pyridin-2-yl-methoxy)phenoxy]indan-1-yl}acetic acid;

4,6-Dibromo-5-[3-isopropyl-4-(5-phenyl-[1,2,4]oxadiazol-3-ylmethoxy)phenoxy]-indan-1-yl} acetic acid;

4-[4-(4,6-Dibromo-1-carboxymethyl-indan-5-yloxy)-2-isopropylphenoxy-methyl]-benzoic acid;

(4,6-Dibromo-5-4-[2-(1*H*-indol-2-yl)ethoxy]-3-isopropylphenoxy}indan-1-yl)acetic acid;

(4,6-Dibromo-5-[3-isopropyl-4-(5-thiophen-3-yl-[1,2,4]oxadiazol-3-yl-methoxy)-phenoxy]indan-1-yl}acetic acid;

{5-[4-(4-Amino-6-phenylamino[1,3,5]triazin-2-ylmethoxy)-3-isopropylphenoxy]-4,6-dibromoindan-1-yl}acetic acid;

{4,6-Dibromo-5-[3-isopropyl-4-(5-methyl-2-phenyloxazol-4-ylmethoxy)phenoxy]-indan-1-yl} acetic acid;

{4,6-Dibromo-5-[4-(3,5-dimethylisoxazol-4-ylmethoxy)-3-isopropylphenoxy]-indan-1-yl}acetic acid;

and pharmaceutically acceptable salts thereof, and stereoisomers thereof.

7. (Currently Amended) A compound according to ~~any one of claims 1 to 6,~~ claim 1, which have one or more asymmetric centers and can exist in the form of racemates, single and multiple enantiomers, as individual diastereomers, with all possible isomers, and mixtures thereof.

8. (Currently Amended) A compound according to ~~any one of claims 1 to 7~~ claim 1, for use in medical therapy.

9. (Currently Amended) A pharmaceutical composition comprising an effective amount of a compound according to ~~any one of claims 1 to 7~~ claim 1, or a pharmaceutically effective salt thereof, together with a pharmaceutically acceptable carrier.

10. (Currently Amended) A method for preventing, inhibiting or treating a disease which is dependent on the expression of a T<sub>3</sub> regulated gene or associated with metabolic dysfunction, which comprises administering to a patient in need of treatment a therapeutically effective amount of a compound according to ~~any one of claims 1 to 7~~ claim 1.

11. (Original) The method according to claim 10 wherein the disease is selected from cardiac arrhythmias, thyrotoxicosis, subclinical hyperthyroidis, certain skin disorders, and certain liver diseases.

12. (Original) The method according to claim 11 wherein the disease is a skin disorder or skin disease.

13. (Original) The method according to claim 12 wherein the skin disorder or skin disease is selected from: keloids, lichen planus, ichthyosis, acne, psoriasis, Dernier's disease, eczema, atopic dermatitis, chloracne, pityriasis, and hirsutism.

14. (Original) The method according to claim 11 wherein the disease is a liver disorder or liver disease.

15. (Original) The method according to claim 14 wherein the liver disorder or liver disease is selected from: chronic alcoholism, acute hepatitis, hepatitis C-induced liver cirrhosis, and liver fibrosis.

16. (Currently Amended) A method to treat ~~certain~~ skin disorders or diseases comprising the step of administering to a patient suffering skin disorders or diseases a pharmaceutical composition comprising ~~by the use of~~ a compound according to ~~any one of claims 1 to 7~~ claim 1 in a combination with a retoid or a Vitamin D analog.

17 - 24. (Cancelled).